Hematological Malignancies | Norton Healthcare

Indication: Hematological Malignancies

A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia

Sub-indication: Warm Hemolytic Anemia

Drug Study

Principal Investigator: Rodney Kosfeld, M.D.
Norton Cancer Institute

Sponsor: Immunovant, Inc.

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.